title: Targeting CSC-related miRNAs for cancer therapy by natural agents.
abstract: The theory of cancer stem cells (CSCs) has provided evidence on fundamental clinical implications because of the involvement of CSCs in cell migration, invasion, metastasis, and treatment resistance, which leads to the poor clinical outcome of cancer patients. Therefore, targeting CSCs will provide a novel therapeutic strategy for the treatment and/or prevention of tumors. However, the regulation of CSCs and its signaling pathways during tumorigenesis are not well understood. MicroRNAs (miRNAs) have been proved to act as key regulators of the post-transcriptional regulation of genes, which involve in a wide array of biological processes including tumorigenesis. The altered expressions of miRNAs are associated with poor clinical outcome of patients diagnosed with a variety of tumors. Therefore, emerging evidence strongly suggest that miRMAs play critical roles in tumor development and progression. Emerging evidence also suggest that miRNAs participate in the regulation of tumor cell growth, migration, invasion, angiogenesis, drug resistance, and metastasis. Moreover, miRNAs such as let-7, miR-21, miR-22, miR-34, miR-101, miR-146a, and miR-200 have been found to be associated with CSC phenotype and function mediated through targeting oncogenic signaling pathways. In this article, we will discuss the role of miRNAs in the regulation of CSC phenotype and function during tumor development and progression. We will also discuss the potential role of naturally occurring agents (nutraceuticals) as potent anti-tumor agents that are believed to function by targeting CSC-related miRNAs.
authors.affiliation: Departments of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA.
authors.forename: Bin
authors.initials: B
authors.lastname: Bao
authors.forename: Yiwei
authors.initials: Y
authors.lastname: Li
authors.forename: Aamir
authors.initials: A
authors.lastname: Ahmad
authors.forename: Asfar S
authors.initials: AS
authors.lastname: Azmi
authors.forename: Ginny
authors.initials: G
authors.lastname: Bao
authors.forename: Shadan
authors.initials: S
authors.lastname: Ali
authors.forename: Sanjeev
authors.initials: S
authors.lastname: Banerjee
authors.forename: Dejuan
authors.initials: D
authors.lastname: Kong
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000302:isolation & purification; D001688:Biological Products / Q000008:administration & dosage* / Q000302:isolation & purification; D016503:Drug Delivery Systems / Q000639:trends*; D006801:Humans; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000502:physiology* / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000473:pathology / Q000502:physiology
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D001688:Biological Products; D035683:MicroRNAs